Background This meta-analysis (PROSPERO-ID: CRD42022362962), pooled effect
estimates of outcomes, from placebo-controlled randomized clinical trials (RCTs) examining …

Objective Retaining adolescents and young adults (AYA) in medications for opioid use
disorder (MOUD), like methadone maintenance treatment (MMT), is critical to reducing toxic …

Following the availability of highly effective direct-acting antivirals (DAAs) to treat hepatitis C
infection, the uptake of treatment by people living with hepatitis C rose dramatically in high …

Objectives Methamphetamine is the second leading cause of overdose death in America
and a leading cause of emergency department (ED) visits. Methamphetamine-induced …

Objective: There is an increase in persons entering substance use treatment who co-use
opioids and methamphetamines in recent years. Co-using these substances may negatively …

Introduction The COVID‐19 pandemic prompted the transition of Australian Self‐
Management and Recovery Training (SMART) Recovery mutual support groups to virtual …

Oxytocin is gaining traction in the treatment of various substance use disorders (SUD). We
performed a systematic review assessing the efficacy of oxytocin for treating different SUD …

The co-occurrence of substance use disorders (SUDs) and psychiatric conditions, often
referred to as comorbidity or concurrent disorders, presents intricate challenges in both …

Background: Stimulant use has substantially increased among people with opioid use
disorder (OUD) and is associated with worse treatment outcomes. This study's objective was …

As a psychoactive substance abused worldwide, methamphetamine (METH) abuse leads to
multiple neurodegenerative symptoms including memory deficits. Terminalia chebula retzius …